Low-dose growth hormone inhibits 11β-hydroxysteroid dehydrogenase type 1 but has no effect upon fat mass in patients with simple obesity

Journal of Clinical Endocrinology and Metabolism

Volumn 88, Issue 5, 2003, Pages 2113-2118

  Tomlinson, Jeremy W ^a   Crabtree, Nicola ^a   Clark, Penny M S ^b   Holder, Geoff ^b   Toogood, Andrew A ^a   Shackleton, Cedric H L ^c   Stewart, Paul M ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

^c CHILDREN S HOSPITAL OAKLAND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE; CORTISONE; HUMAN GROWTH HORMONE; HYDROCORTISONE; SOMATOMEDIN;

ADULT; ARTICLE; BODY COMPOSITION; BODY FAT; BODY MASS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; FOLLOW UP; HORMONE BLOOD LEVEL; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYDROCORTISONE RELEASE; LOW DRUG DOSE; MALE; OBESITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SELF INJECTION; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME;

11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 2; ADIPOCYTES; ADIPOSE TISSUE; BLOOD PRESSURE; BODY COMPOSITION; CELL DIFFERENTIATION; CELL DIVISION; CORTISONE; DOUBLE-BLIND METHOD; ENZYME INHIBITORS; HUMAN GROWTH HORMONE; HYDROCORTISONE; HYDROXYSTEROID DEHYDROGENASES; INSULIN; INSULIN-LIKE GROWTH FACTOR I; LIPIDS; OBESITY; PLACEBOS;

EID: 0038030838     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.2002-021894     Document Type: Article

References (40)

1. Bender R, Jockel KH, Trautner C, Spraul M, Berger M 1999 Effect of age on excess mortality in obesity. JAMA 281:1498-1504
2. Fontbonne A, Thibult N, Eschwege E, Ducimetiere P 1992 Body fat distribution and coronary heart disease mortality in subjects with impaired glucose tolerance or diabetes mellitus: the Paris Prospective Study, 15-year follow-up. Diabetologia 35:464-468
3. Casassus P, Fontbonne A, Thibult N, Ducimetiere P, Richard JL, Claude JR, Warnet JM, Rosselin G, Eschwege E 1992 Upper-body fat distribution: a hyperinsulinemia-independent predictor of coronary heart disease mortality. The Paris Prospective Study. Arterioscler Thromb 12:1387-1392
4. Williams T, Berelowitz M, Joffe SN, Thorner MO, Rivier J, Vale W, Frohman LA 1984 Impaired growth hormone responses to growth hormone-releasing factor in obesity. A pituitary defect reversed with weight reduction. N Engl J Med 311:1403-1407
5. Kanaley JA, Weatherup-Dentes MM, Jaynes EB, Hartman ML 1999 Obesity attenuates the growth hormone response to exercise. J Clin Endocrinol Metab 84:3156-3161
6. Vahl N, Jorgensen JO, Skjaerbaek C, Veldhuis JD, Orskov H, Christiansen JS 1997 Abdominal adiposity rather than age and sex predicts mass and regularity of GH secretion in healthy adults. Am J Physiol 272(6 Pt 1):E1108-E1116
7. Weaver JU, Monson JP, Noonan K, John WG, Edwards A, Evans KA, Cunningham J 1995 The effect of low dose recombinant human growth hormone replacement on regional fat distribution, insulin sensitivity, and cardiovascular risk factors in hypopituitary adults. J Clin Endocrinol Metab 80:153-159
8. Beshyah SA, Freemantle C, Thomas E, Rutherford O, Page B, Murphy M, Johnston DG 1995 Abnormal body composition and reduced bone mass in growth hormone deficient hypopituitary adults. Clin Endocrinol (Oxf) 42:179-189
9. Bengtsson BA, Brummer RJ, Eden S, Bosaeus I 1989 Body composition in acromegaly. Clin Endocrinol (Oxf) 30:121-130
10. Snyder DK, Clemmons DR, Underwood LE 1988 Treatment of obese, diet-restricted subjects with growth hormone for 11 weeks: effects on anabolism, lipolysis, and body composition. J Clin Endocrinol Metab 67:54-61
11. Drent ML, Wever LD, Ader HJ, van der Veen EA 1995 Growth hormone administration in addition to a very low calorie diet and an exercise program in obese subjects. Eur J Endocrinol 132:565-572
12. Thompson JL, Butterfield GE, Gylfadottir UK, Yesavage J, Marcus R, Hintz RL, Pearman A, Hoffman AR 1998 Effects of human growth hormone, insulin-like growth factor I, and diet and exercise on body composition of obese postmenopausal women. J Clin Endocrinol Metab 83:1477-1484
13. Johannsson G, Marin P, Lonn L, Ottosson M, Stenlof K, Bjorntorp P, Sjostrom L, Bengtsson BA 1997 Growth hormone treatment of abdominally obese men reduces abdominal fat mass, improves glucose and lipoprotein metabolism, and reduces diastolic blood pressure. J Clin Endocrinol Metab 82:727-734
14. Kim KR, Nam SY, Song YD, Lim SK, Lee HC, Huh KB 1999 Low-dose growth hormone treatment with diet restriction accelerates body fat loss, exerts anabolic effect and improves growth hormone secretory dysfunction in obese adults. Horm Res 51:78-84
15. Fraser R, Ingrain MC, Anderson NH, Morrison C, Davies E, Connell JM 1999 Cortisol effects on body mass, blood pressure, and cholesterol in the general population. Hypertension 33:1364-1368
16. Ricketts ML, Verhaeg JM, Bujalska I, Howie AJ, Rainey WE, Stewart PM 1998 Immunohistochemical localization of type 1 11β-hydroxysteroid dehydrogenase in human tissues. J Clin Endocrinol Metab 83:1325-1335
17. Bujalska IJ, Kumar S, Stewart PM 1997 Does central obesity reflect "Cushing's disease of the omentum"? Lancet 349:1210-1213
18. Masuzaki H, Paterson J, Shinyama H, Morton NM, Mullins JJ, Seckl JR, Flier JS 2001 A transgenic model of visceral obesity and the metabolic syndrome. Science 294:2166-2170
19. Moore JS, Monson JP, Kaltsas G, Putignano P, Wood PJ, Sheppard MC, Besser GM, Taylor NF, Stewart PM 1999 Modulation of 11β-hydroxysteroid dehydrogenase isozymes by growth hormone and insulin-like growth factor: in vivo and in vitro studies. J Clin Endocrinol Metab 84:4172-4177
20. Tomlinson JW, Moore J, Cooper MS, Bujalska I, Shahmanesh M, Burt C, Strain A, Hewison M, Stewart PM 2001 Regulation of expression of 11β-hydroxysteroid dehydrogenase type 1 in adipose tissue: tissue-specific induction by cytokines. Endocrinology 142:1982-1989
21. Palermo M, Shackleton CH, Mantero F, Stewart PM 1996 Urinary free cortisone and the assessment of 11 β-hydroxysteroid dehydrogenase activity in man. Clin Endocrinol (Oxf) 45:605-611
22. Stewart PM, Boulton A, Kumar S, Clark PM, Shackleton CH 1999 Cortisol metabolism in human obesity: impaired cortisone->cortisol conversion in subjects with central adiposity. J Clin Endocrinol Metab 84:1022-1027
23. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC 1985 Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412-419
24. Snyder DK, Underwood LE, Clemmons DR 1995 Persistent lipolytic effect of exogenous growth hormone during caloric restriction. Am J Med 98:129-134
25. Ottosson M, Lonnroth P, Bjorntorp P, Eden S 2000 Effects of cortisol and growth hormone on lipolysis in human adipose tissue. J Clin Endocrinoi Metab 85:799-803
26. Smith PJ, Wise LS, Berkowitz R, Wan C, Rubin CS 1988 Insulin-like growth factor-I is an essential regulator of the differentiation of 3T3-L1 adipocytes. J Biol Chem 263:9402-9408
27. Soret B, Lee HJ, Finley E, Lee SC, Vernon RG 1999 Regulation of differentiation of sheep subcutaneous and abdominal preadipocytes in culture. J Endocrinol 161:517-524
28. Richardson RL, Hausman GJ, Gaskins HR 1992 Effect of transforming growth factor-β on insulin-like growth factor 1- and dexamethasone-induced proliferation and differentiation in primary cultures of pig preadipocytes. Acta Anat (Basel) 145:321-326
29. Low SC, Chapman KE, Edwards CR, Wells T, Robinson IC, Seckl JR 1994 Sexual dimorphism of hepatic 11 β-hydroxysteroid dehydrogenase in the rat: the role of growth hormone patterns. J Endocrinol 143:541-548
30. Weaver JU, Thaventhiran L, Noonan K, Burrin JM, Taylor NF, Norman MR, Monson JP 1994 The effect of growth hormone replacement on cortisol metabolism and glucocorticoid sensitivity in hypopituitary adults. Clin Endocrinol (Oxf) 41:639-648
31. Gelding SV, Taylor NF, Wood PJ, Noonan K, Weaver JU, Wood DF, Monson JP 1998 The effect of growth hormone replacement therapy on cortisol-cortisone interconversion in hypopituitary adults: evidence for growth hormone modulation of extrarenal 11 β-hydroxysteroid dehydrogenase activity. Clin Endocrinol (Oxf) 48:153-162
32. Trainer PJ, Drake WM, Perry LA, Taylor NF, Besser GM, Monson JP 2001 Modulation of cortisol metabolism by the growth hormone receptor antagonist Pegvisomant in patients with acromegaly. J Clin Endocrinol Metab 86:2989-2992
33. Tomlinson JW, Sinha B, Bujalska I, Hewison M, Stewart PM 2002 Expression of 11 β-hydroxysteroid dehydrogenase type 1 in adipose tissue is not increased in human obesity. J Clin Endocrinol Metab 87:5630-5635
34. Rask E, Olsson T, Soderberg S, Andrew R, Livingstone DE, Johnson O, Walker BR 2001 Tissue-specific dysregulation of cortisol metabolism in human obesity. J Clin Endocrinol Metab 86:1418-1421
35. Rask E, Walker BR, Soderberg S, Livingstone DE, Eliasson M, Johnson O, Andrew R, Olsson T 2002 Tissue-specific changes in peripheral cortisol metabolism in obese women: increased adipose 11β-hydroxysteroid dehydrogenase type 1 activity. J Clin Endocrinol Metab 87:3330-3336
36. Paulmyer-Lacroix O, Boullu S, Oliver C, Alessi MC, Grino M 2002 Expression of the mRNA coding for 11β-hydroxysteroid dehydrogenase type 1 in adipose tissue from obese patients: an in situ hybridizahon study. J Clin Endocrinol Metab 87:2701-2705
37. Bujalska IJ, Kumar S, Hewison M, Stewart PM 1999 Differentiation of adipose stromal cells: the roles of glucocorticoids and 11β-hydroxysteroid dehydrogenase. Endocrinology 140:3188-3196
38. Walker BR, Connacher AA, Lindsay RM, Webb DJ, Edwards CR 1995 Carbenoxolone increases hepatic insulin sensitivity in man: a novel role for 11-oxosteroid reductase in enhancing glucocorticotd receptor activation. J Clin Endocrinol Metab 80:3155-3159
39. Barf T, Vallgarda J, Emond R, Haggstrom C, Kurz G, Nygren A, Larwood V, Mosialou E, Axelsson K, Olsson R, Engblom L, Edling N, Ronquist-Nii Y, Ohman B, Alberts P, Abrahmsen L 2002 Arylsulfonamidothiazoles as a new class of potential antidiabetic drugs. Discovery of potent and selective inhibitors of the 11β-hydroxysteroid dehydrogenase type 1. J Med Chem 45:3813-3815
40. Toogood AA, Taylor NF, Shalet SM, Monson JP 2000 Modulation of cortisol metabolism by low-dose growth hormone replacement in elderly hypopituitary patients. J Clin Endocrinol Metab 85:1727-1730